Zhifei Biotech (300122.SZ): Application for clinical trial of freeze-dried human rabies vaccine (ZFB-3 cells) accepted

Zhitong Finance App News, Zhifei Biotech (300122.SZ) issued an announcement. The company recently learned that the freeze-dried human rabies vaccine (ZFB-3 cells) developed by the wholly-owned subsidiary Anhui Zhifeilong Kema Biopharmaceutical Co., Ltd. has obtained a notice of acceptance of the drug clinical trial application from the State Drug Administration. This medicine is used to prevent rabies. By receiving this vaccine, the body can be stimulated to produce immunity against the rabies virus. The drug uses a human diploid cell line (ZFB-3 cell) independently developed by the company as a production substrate. Compared with the animal-derived cellular rabies vaccine, the incidence of local and systemic adverse reactions is theoretically smaller, and there is no risk of tumorigenicity.